Cat. No. 2906
Alternative Name: Olesoxime
Chemical Name: Cholest-4-en-3-one oxime
Biological ActivityNeuroprotective and neuroregenerative compound. Rescues motor neurons from axotomy-induced cell death and promotes nerve regeneration following sciatic nerve crush in vivo. Binds directly to two components of the mitochondrial permeability pore, the voltage-dependent anion channel (VDAC) and translocator protein; thought to inhibit MPTP opening.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Bordet et al (2007) Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J.Pharmacol.Exp.Ther. 322 709. PMID: 17496168.
If you know of a relevant reference for TRO 19622 please let us know.
Citations are publications that use Tocris products. Selected citations for TRO 19622 include:
González et al (2016) Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies. Front Neurosci 126 1023. PMID: 26878172.
Skals et al (2014) Bacterial RTX toxins allow acute ATP release from human erythrocytes directly through the toxin pore. J Biol Chem 289 19098. PMID: 24860098.
Do you know of a great paper that uses TRO 19622 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TRO 19622, supplier, Neuroprotective, neuroregenerative, Binds, voltage-dependent, anion, VDAC, Channels, modulators, Other, TRO19622, mitochondrial, pore, MPTP, olesoxime, spinal, muscular, atrophy, SMA, Tocris Bioscience, Other Channel Modulator products
Find multiple products by catalog number
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.